N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
N/A N=98 Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease
Crohn's Disease
Primary: Diagnostic Yield in Suspected Crohn's Patients (CE Prior to IC vs. IC and SBFT) — 97.3; 57.3 percentage of yield — p=<0.0001
N/A N=158 Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
Crohn Disease
Primary: Accuracy of CE Versus IC Plus MRE for Detecting Active Crohn's Disease (CD), by Visualizing the Small Bowel and Colon in Subjects With Know CD and Mucosal Disease. — 94…
Phase 2 N=75 PillCam® Platform With the PillCam Crohn's Disease Capsule
Crohn's Disease
Primary: Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within…
N/A N=191 Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
Crohn Disease
Primary: Percentage of Participants That Achieved Symptomatic Remission at Week 6 — 40; 46 Participants
Phase 3 N=112 Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Crohn's Disease
Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526
N/A N=15 The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm
Phase 2 N=262 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Phase 2 N=54 Dietary Treatment of Crohn's Disease
Crohn's Disease · Inflammatory Bowel Disease
Primary: Number of Participants With Flare Up of Crohn's Disease Through Month 12 — 6; 4; 0 participants
N/A N=67 A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients
Crohn Disease
Primary: Maintenance of Symptomatic Remission, Without Worsening of Any Existing Disease Activity During Study Period — -31.63; -27.57 score on a scale — p=0.469
Phase 3 N=396 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Crohn's Disease
Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001
Phase 2 N=40 Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
Crohn's Disease
Primary: • Evaluate the Effectiveness of the PillCam COLON 2 Bowel Prep Regimen in Crohn's Disease Patients — 62; 79 percentage of participants
Phase 3 N=108 Safety Study of Entocort for Children With Crohn's Disease
Crohn's Disease
Primary: Adverse Event — 79 Patients
Phase 2 N=78 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Small Bowel Crohn's Disease
Primary: Percentage of Participants Who Achieved Clinical Remission at Week 24 — 25.0; 25.0; 16.7 percentage of participants
Phase 2 N=33 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
N/A N=70 The Effect of Riboflavin in Crohn's Disease
Crohn Disease
Primary: F. Prausnitzii (FISH Analysis). — 4.53; 5.07; 6.19; 5.46 Relative FISH counts from total bacteria
N/A N=74 Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects
Known Crohn Disease Subjects
Primary: Mucosal Change in VCE (Video Capsule Endoscopy) Mucosal Scores and PGA (Physician Global Assessment) — -0.3; -382.9; -2.7 units on a scale — p=0.631
Phase 2 N=10 Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
N/A N=19 Crohn Disease Exclusion Diet After Single Medication De-escalation
Crohn Disease
Primary: Sustained Relapse-free Remission — 6; 5 Participants
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Phase 2 N=8 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
N/A N=45 Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
N/A N=61 Eating Behaviour in Crohn's Disease
Crohn's Disease
Primary: Dietary Recalls (Calorific Intake) — 1900.9; 2054.3 kcal
Phase 2 N=40 The Effects of Naltrexone on Active Crohn's Disease
Inflammation · Crohn's Disease
Primary: Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores; — 40; 88 percentage of pts — p=0.009
Phase 2 N=77 Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
Crohn's Disease
Primary: Number of Participants Who Had Remission of Crohn's Disease After 8-week Treatment — 6; 7; 3 Participants
Phase 3 N=244 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010
N/A N=326 A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants